Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TENAX THERAPEUTICS, INC.

(TENX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Number of employees : 9 people.
Managers
NameAgeSinceTitle
Anthony A. DiTonno712018Chief Executive Officer & Director
Michael B. Jebsen482018President & Chief Financial Officer
Stuart Rich, Dr.702021Director & Chief Medical Officer
Doug Randall-2013Executive VP-Commercial & Business Operations
Gerald T. Proehl612021Chairman
James P. Mitchum672015Independent Director
Steven Joseph Boyd392020Independent Director
Illya Keith Maher, Dr.522020Independent Director
June Sherie Almenoff, Dr.632021Independent Director
Michael H. Davidson, Dr.632021Independent Director
Members of the board
NameAgeSinceTitle
Gerald T. Proehl612021Chairman
Anthony A. DiTonno712018Chief Executive Officer & Director
James P. Mitchum672015Independent Director
Steven Joseph Boyd392020Independent Director
Illya Keith Maher, Dr.522020Independent Director
Stuart Rich, Dr.702021Director & Chief Medical Officer
June Sherie Almenoff, Dr.632021Independent Director
Michael H. Davidson, Dr.632021Independent Director
Declan Doogan692021Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,969,312 10,027,187 67.0% 0 0.0% 67.0%
Stock B 0 10,232 0 0.0% 0 0.0%
Stock C 0 5,181,346 0 0.0% 5,181,136 100.0%
Shareholders
NameEquities%
Stuart Rich 4,243,517 28.3%
Declan Doogan 3,637,871 24.3%
Armistice Capital LLC 2,019,995 13.5%
Renaissance Technologies LLC 747,832 5.00%
Michael H. Davidson 606,645 4.05%
BlackRock Fund Advisors 598,475 4.00%
Tang Capital Management LLC 460,000 3.07%
The Vanguard Group, Inc. 173,801 1.16%
RA Capital Management LP 119,485 0.80%
Broadfin Capital LLC 98,432 0.66%
Company contact information
Tenax Therapeutics, Inc.
ONE Copley Parkway
Suite 490
Morrisville, NC 27560

Phone : +1.919.855.2100
Fax : +1.919.855.2133
Web : http://www.tenaxthera.com
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
TENAX THERAPEUTICS, INC.3.23%48
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102
PHARMARON BEIJING CO., LTD.62.65%23 432
CUREVAC N.V.-23.60%21 497
ALNYLAM PHARMACEUTICALS, INC.36.10%20 793
INCYTE CORPORATION-3.47%18 465
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.41.56%17 774
BIO-TECHNE CORPORATION36.01%16 797
PPD, INC.35.36%16 288
NOVAVAX, INC.56.24%12 918
ICON PUBLIC LIMITED COMPANY8.82%11 215
PRA HEALTH SCIENCES, INC.33.28%10 833
QIAGEN N.V.-10.84%10 763
CRISPR THERAPEUTICS AG-16.51%10 242
GENSCRIPT BIOTECH CORPORATION191.22%8 779
SYNEOS HEALTH, INC.23.94%8 746